Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Tursz

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 26, 2002
An interview with Professor Thomas TurszThomas Tursz
Nature Biotechnology|November 8, 2005
In vivo veritasLaurence Zitvogel, Thomas Tursz
Molecular Oncology|September 18, 2014
Hurdles on the road to personalized medicineThomas Tursz, Rene Bernards
European Journal of Cancer (Oxford, England : 1990)|March 14, 2008
Managing cancer in the EU: the Organisation of European Cancer Institutes (OECI)Ulrik Ringborg, Marco Pierotti, Guy Storme, et al.
Personalized Medicine|May 23, 2018
Personalized immunotherapy: a siren myth?Antoine Tesniere, Guido Kroemer, Thomas Tursz, et al.
Bulletin De L'Academie Nationale De Medecine|July 1, 2016
[Not Available]Martine Perez, Roland Masse, Thomas Tursz, et al.
Cancer Treatment Reviews|December 3, 2014
Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?Monica Arnedos, Jean-Charles Soria, Fabrice Andre, et al.
Nature Reviews. Clinical Oncology|March 3, 2011
WIN Consortium--challenges and advancesJohn Mendelsohn, Thomas Tursz, Richard L Schilsky, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|October 21, 2009
Imatinib mesylate (Gleevec): targeted therapy against cancer with immune propertiesMoustapha Zoubir, Thomas Tursz, Cédric Ménard, et al.
Nature Reviews. Clinical Oncology|March 3, 2011
Implications of personalized medicine--perspective from a cancer centerThomas Tursz, Fabrice Andre, Vladimir Lazar, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|March 26, 2002
An interview with Professor Thomas TurszThomas Tursz
Nature Biotechnology|November 8, 2005
In vivo veritasLaurence Zitvogel, Thomas Tursz
Molecular Oncology|September 18, 2014
Hurdles on the road to personalized medicineThomas Tursz, Rene Bernards
European Journal of Cancer (Oxford, England : 1990)|March 14, 2008
Managing cancer in the EU: the Organisation of European Cancer Institutes (OECI)Ulrik Ringborg, Marco Pierotti, Guy Storme, et al.
Personalized Medicine|May 23, 2018
Personalized immunotherapy: a siren myth?Antoine Tesniere, Guido Kroemer, Thomas Tursz, et al.
Bulletin De L'Academie Nationale De Medecine|July 1, 2016
[Not Available]Martine Perez, Roland Masse, Thomas Tursz, et al.
Cancer Treatment Reviews|December 3, 2014
Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?Monica Arnedos, Jean-Charles Soria, Fabrice Andre, et al.
Nature Reviews. Clinical Oncology|March 3, 2011
WIN Consortium--challenges and advancesJohn Mendelsohn, Thomas Tursz, Richard L Schilsky, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|October 21, 2009
Imatinib mesylate (Gleevec): targeted therapy against cancer with immune propertiesMoustapha Zoubir, Thomas Tursz, Cédric Ménard, et al.
Nature Reviews. Clinical Oncology|March 3, 2011
Implications of personalized medicine--perspective from a cancer centerThomas Tursz, Fabrice Andre, Vladimir Lazar, et al.
Pageof 5